Dr Reddys Laboratories Ltd vs Glaxosmithkline Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 12, 2026

Key Highlights

The Latest Trading Price of Dr Reddys Laboratories Ltd is ₹ 1270 as of 12 May 15:30 . The P/E Ratio of Dr Reddys Laboratories Ltd changed from 38.5 on March 2021 to 16.9 on March 2025 . This represents a CAGR of -15.18% over 5 yearsThe P/E Ratio of Glaxosmithkline Pharmaceuticals Ltd changed from 68.1 on March 2021 to 52.5 on March 2025 . This represents a CAGR of -5.07% over 5 years The Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 75095 crore on March 2021 to ₹ 95465 crore on March 2025 . This represents a CAGR of 4.92% over 5 yearsThe Market Cap of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 24401 crore on March 2021 to ₹ 48743 crore on March 2025 . This represents a CAGR of 14.84% over 5 years The revenue of Dr Reddys Laboratories Ltd for the Mar '26 is ₹ 8026 crore as compare to the Dec '25 revenue of ₹ 9024 crore. This represent the decline of -11.06% The revenue of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 1091 crore. This represent the decline of -100% The ebitda of Dr Reddys Laboratories Ltd for the Mar '26 is ₹ 862.5 crore as compare to the Dec '25 ebitda of ₹ 2158 crore. This represent the decline of -60.04% The ebitda of Glaxosmithkline Pharmaceuticals Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 421.44 crore. This represent the decline of -100% The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1392 crore to ₹ 221.3 crore over 8 quarters. This represents a CAGR of -60.13% The net profit of Glaxosmithkline Pharmaceuticals Ltd changed from ₹ 182.33 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Dr Reddys Laboratories Ltd changed from 19.03 % on March 2021 to 12.47 % on March 2025 . This represents a CAGR of -8.11% over 5 yearsThe Dividend Payout of Glaxosmithkline Pharmaceuticals Ltd changed from 142.13 % on March 2021 to 99.54 % on March 2025 . This represents a CAGR of -6.88% over 5 years .

About Dr Reddys Laboratories Ltd

Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's portfolio of products and services include Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Dr. Reddy's operates in markets across the globe.
Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as 'Glindia Limited' in November, 1924.
The Company' s name was changed to Glaxo (India) Limited' from Glindia Limited in year 1987 and further to 'GlaxoSmithKline Pharmaceuticals Limited' from Glaxo (India) Limited effective from October 22, 2001. GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of UK-based GSK Plc., a global biopharma company to unite science, technology and talent to get ahead of disease together.
The Company is headquartered in Mumbai and it has six branch offices, one manufacturing facility at Nashik in Maharashtra, 20 contract manufacturing organisations (CMOs) with regional and sales hubs across India.
The Company is engaged interalia, in the business of manufacturing, distributing and trading in pharmaceuticals.

FAQs for the comparison of Dr Reddys Laboratories Ltd and Glaxosmithkline Pharmaceuticals Ltd

Which company has a larger market capitalization, Dr Reddys Laboratories Ltd or Glaxosmithkline Pharmaceuticals Ltd?

Market cap of Dr Reddys Laboratories Ltd is 106,009 Cr while Market cap of Glaxosmithkline Pharmaceuticals Ltd is 41,472 Cr

What are the key factors driving the stock performance of Dr Reddys Laboratories Ltd and Glaxosmithkline Pharmaceuticals Ltd?

The stock performance of Dr Reddys Laboratories Ltd and Glaxosmithkline Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Dr Reddys Laboratories Ltd and Glaxosmithkline Pharmaceuticals Ltd?

As of May 12, 2026, the Dr Reddys Laboratories Ltd stock price is INR ₹1270.1. On the other hand, Glaxosmithkline Pharmaceuticals Ltd stock price is INR ₹2448.1.

How do dividend payouts of Dr Reddys Laboratories Ltd and Glaxosmithkline Pharmaceuticals Ltd compare?

To compare the dividend payouts of Dr Reddys Laboratories Ltd and Glaxosmithkline Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.